Rafferty Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.42M | Sell |
35,018
-13,541
| -28% | -$2.5M | 0.03% | 309 |
|
|
2025
Q4 | $8.55M | Sell |
48,559
-110,068
| -69% | -$18M | 0.03% | 282 |
|
|
2025
Q3 | $22.2M | Sell |
158,627
-21,813
| -12% | -$2.95M | 0.07% | 144 |
|
|
2025
Q2 | $22.7M | Sell |
180,440
-335
| -0.2% | -$41.7K | 0.07% | 137 |
|
|
2025
Q1 | $24.7M | Sell |
180,775
-8,745
| -5% | -$1.25M | 0.11% | 118 |
|
|
2024
Q4 | $29M | Buy |
189,520
+29,319
| +18% | +$4.95M | 0.1% | 120 |
|
|
2024
Q3 | $31.1M | Buy |
160,201
+8,906
| +6% | +$1.86M | 0.11% | 107 |
|
|
2024
Q2 | $35.1M | Buy |
151,295
+38,479
| +34% | +$8.36M | 0.13% | 91 |
|
|
2024
Q1 | $24.3M | Buy |
112,816
+16,934
| +18% | +$3.97M | 0.09% | 117 |
|
|
2023
Q4 | $24.8M | Buy |
95,882
+13,335
| +16% | +$3.28M | 0.1% | 117 |
|
|
2023
Q3 | $21.2M | Buy |
82,547
+17,754
| +27% | +$4.75M | 0.12% | 110 |
|
|
2023
Q2 | $18.5M | Buy |
64,793
+5,628
| +10% | +$1.68M | 0.1% | 121 |
|
|
2023
Q1 | $16.4M | Buy |
59,165
+2,794
| +5% | +$773K | 0.11% | 123 |
|
|
2022
Q4 | $15.6M | Sell |
56,371
-16,459
| -23% | -$4.65M | 0.13% | 122 |
|
|
2022
Q3 | $19.4M | Buy |
72,830
+17,895
| +33% | +$3.8M | 0.21% | 80 |
|
|
2022
Q2 | $11.2M | Sell |
54,935
-8,299
| -13% | -$1.7M | 0.1% | 120 |
|
|
2022
Q1 | $13.3M | Buy |
63,234
+18,274
| +41% | +$3.97M | 0.08% | 152 |
|
|
2021
Q4 | $10.8M | Buy |
44,960
+15,793
| +54% | +$4.06M | 0.06% | 174 |
|
|
2021
Q3 | $8.25M | Buy |
29,167
+9,718
| +50% | +$3.19M | 0.06% | 191 |
|
|
2021
Q2 | $6.74M | Sell |
19,449
-9,647
| -33% | -$2.92M | 0.04% | 251 |
|
|
2021
Q1 | $8.14M | Buy |
29,096
+7,355
| +34% | +$1.98M | 0.06% | 192 |
|
|
2020
Q4 | $5.32M | Buy |
21,741
+857
| +4% | +$221K | 0.05% | 206 |
|
|
2020
Q3 | $5.92M | Buy |
20,884
+2,815
| +16% | +$785K | 0.07% | 163 |
|
|
2020
Q2 | $4.83M | Buy |
18,069
+6,856
| +61% | +$2.06M | 0.07% | 176 |
|
|
2020
Q1 | $3.55M | Sell |
11,213
-14,833
| -57% | -$4.5M | 0.15% | 81 |
|
|
2019
Q4 | $7.73M | Sell |
26,046
-10,611
| -29% | -$2.94M | 0.12% | 98 |
|
|
2019
Q3 | $8.53M | Sell |
36,657
-3,439
| -9% | -$801K | 0.13% | 83 |
|
|
2019
Q2 | $9.38M | Buy |
40,096
+11,237
| +39% | +$2.59M | 0.16% | 70 |
|
|
2019
Q1 | $6.82M | Buy |
28,859
+23,281
| +417% | +$7.33M | 0.11% | 99 |
|
|
2018
Q4 | $1.68M | Sell |
5,578
-491
| -8% | -$157K | 0.04% | 248 |
|
|
2018
Q3 | $2.14M | Sell |
6,069
-8,598
| -59% | -$2.96M | 0.03% | 277 |
|
|
2018
Q2 | $4.26M | Buy |
14,667
+5,752
| +65% | +$1.62M | 0.06% | 156 |
|
|
2018
Q1 | $2.44M | Buy |
8,915
+4,383
| +97% | +$1.36M | 0.04% | 240 |
|
|
2017
Q4 | $1.44M | Sell |
4,532
-335
| -7% | -$107K | 0.02% | 354 |
|
|
2017
Q3 | $1.52M | Sell |
4,867
-814
| -14% | -$241K | 0.03% | 317 |
|
|
2017
Q2 | $1.54M | Buy |
5,681
+1,516
| +36% | +$401K | 0.04% | 245 |
|
|
2017
Q1 | $1.14M | Buy |
4,165
+649
| +18% | +$184K | 0.03% | 321 |
|
|
2016
Q4 | $997K | Buy |
3,516
+1,104
| +46% | +$327K | 0.05% | 199 |
|
|
2016
Q3 | $755K | Sell |
2,412
-56
| -2% | -$16.6K | 0.03% | 232 |
|
|
2016
Q2 | $0 | Sell |
2,468
-638
| -21% | -$168K | ﹤0.01% | 508 |
|
|
2016
Q1 | $809K | Sell |
3,106
-6,171
| -67% | -$1.63M | 0.04% | 283 |
|
|
2015
Q4 | $2.86M | Buy |
9,277
+1,533
| +20% | +$441K | 0.34% | 61 |
|
|
2015
Q3 | $2.26M | Buy |
7,744
+5,205
| +205% | +$1.72M | 0.18% | 118 |
|
|
2015
Q2 | $1.03M | Sell |
2,539
-231
| -8% | -$92.7K | 0.07% | 218 |
|
|
2015
Q1 | $1.17M | Buy |
2,770
+1,154
| +71% | +$455K | 0.09% | 205 |
|
|
2014
Q4 | $549K | Buy |
1,616
+296
| +22% | +$95.8K | 0.12% | 175 |
|
|
2014
Q3 | $437K | Buy |
1,320
+557
| +73% | +$184K | 0.05% | 174 |
|
|
2014
Q2 | $241K | Sell |
763
-520
| -41% | -$157K | 0.05% | 279 |
|
|
2014
Q1 | $392K | Sell |
1,283
-161
| -11% | -$51.1K | 0.08% | 113 |
|
|
2013
Q4 | $404K | Buy |
+1,444
| New | +$373K | 0.1% | 129 |
|
Other funds holding BIIB
VCM
VPM
Rafferty Asset Management's BIIB Position: Q1 2026 in Review
Rafferty Asset Management reduced its Biogen (BIIB) stake by 28% in Q1 2026, selling an estimated $2.5M and leaving 35,018 shares worth $6.42M. The position accounts for 0.03% of the portfolio, ranked #309.
Rafferty Asset Management first reported a position in BIIB in Q4 2013 and has held it in 50 quarters since. The position peaked at $35.1M in Q2 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Rafferty Asset Management held 35,018 shares of Biogen worth $6.42M as of Q1 2026.
- Rafferty Asset Management sold 13,541 Biogen shares in Q1 2026, an estimated $2.5M.
- Biogen made up 0.03% of Rafferty Asset Management's portfolio in Q1 2026, its #309 holding.
- Rafferty Asset Management first reported a position in Biogen in Q4 2013 and has held it in 50 quarters since.
- Rafferty Asset Management's Biogen position peaked at $35.1M in Q2 2024.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.